Curaleaf International Launches a Range of Medical Cannabis Products in Australia

Curaleaf Holdings (CURLF) has announced its entry into the Australian medical cannabis market through the launch of Curaleaf branded products.

Rhea-AI Summary

Curaleaf Holdings (CURLF) has announced its entry into the Australian medical cannabis market through the launch of Curaleaf branded products. The initial offering includes four cannabis flower strains that will be distributed through Canngea, a licensed Australian manufacturer and wholesaler.

The company plans to expand its portfolio in the coming months with precision-dosed inhalation formats and popular strains currently prescribed in the UK, Germany, and other European markets. The Australian market is projected to exceed $1 billion in annual sales next year, representing a significant opportunity for Curaleaf's global expansion strategy.

Positive

• Entry into Australia's rapidly growing medical cannabis market, expected to reach $1B+ in annual sales next year
• Partnership with established local distributor Canngea for market access
• Planned expansion of product portfolio with proven formulations from European markets

Negative

• None.

Argus Session date unavailable

+0.12% session move Open Argus

Details

News Market Reaction – CURLF

The recorded move for CURLF in the trading session of this news was +0.12%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, May 15, 2025 /PRNewswire/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) a leading international provider of medical cannabis products, today announced the launch of Curaleaf branded products in Australia. This announcement marks the expansion of Curaleaf's presence in one of the world's fastest growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity, and patient care.

The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services.

Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the UK, Germany, and other key European markets.

Juan Martinez, Head of Curaleaf International, commented: "Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains."

Boris Jordan, Chairman and CEO of Curaleaf, added: "Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're bringing a proven portfolio and a strong track record of innovation, with more to come."

About Curaleaf International
Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis.

Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.

Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.

Media Contact:
Curaleaf International:
Beth Sweet-Escott
Head of Communications, Curaleaf International
media@curaleafint.com 

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What products is Curaleaf (CURLF) launching in Australia?

Curaleaf is initially launching four cannabis flower strains in Australia, with plans to expand to precision-dosed inhalation formats and popular strains from European markets.

How big is the Australian medical cannabis market where Curaleaf (CURLF) is expanding?

The Australian medical cannabis market is expected to surpass $1 billion in annual sales next year, making it one of the world's fastest-growing medical cannabis markets.

Who is Curaleaf's distribution partner in Australia?

Curaleaf has partnered with Canngea, a licensed Australian manufacturer and wholesaler with experience in medical cannabis, for distribution of their products.

What are Curaleaf's (CURLF) expansion plans for the Australian market?

Curaleaf plans to broaden its portfolio in Australia over the coming months, including introducing precision-dosed inhalation formats and popular strains from UK, German, and other European markets.